U.K. preparing for value-based drug-pricing system

03/24/2013 | Reuters

Beginning in 2014, Britain's National Institute for Health and Clinical Excellence will approve and price drugs based on broader measures, including the benefits to society. Firms with innovative, badly needed or highly effective medications, for example, could command higher prices. The new value-based initiative will replace the current system that caps the maximum return on investments that drug companies can earn.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC